Ming-Zhong Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/538658/publications.pdf

Version: 2024-02-01

45 papers 1,377 citations

411340 20 h-index 388640 36 g-index

48 all docs 48 docs citations

48 times ranked

2612 citing authors

#	Article	IF	Citations
1	MiR-4521 plays a tumor repressive role in growth and metastasis of hepatocarcinoma cells by suppressing phosphorylation of FAK/AKT pathway via targeting FAM129A. Journal of Advanced Research, 2022, 36, 147-161.	4.4	13
2	ETV6 Regulates Hemin-Induced Erythroid Differentiation of K562 Cells through Mediating the Raf/MEK/ERK Pathway. Biological and Pharmaceutical Bulletin, 2022, 45, 250-259.	0.6	2
3	33-kDa ANXA3 isoform contributes to hepatocarcinogenesis via modulating ERK, PI3K/Akt-HIF and intrinsic apoptosis pathways. Journal of Advanced Research, 2021, 30, 85-102.	4.4	12
4	CRKL promotes hepatocarcinoma through enhancing glucose metabolism of cancer cells via activating PI3K/Akt. Journal of Cellular and Molecular Medicine, 2021, 25, 2714-2724.	1.6	6
5	Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson's disease model through inhibition of microglial activation. NeuroToxicology, 2021, 83, 129-136.	1.4	25
6	The potential role of miR-124-3p in tumorigenesis and other related diseases. Molecular Biology Reports, 2021, 48, 3579-3591.	1.0	10
7	Weighted Gene Coexpression Network Analysis in Mouse Livers following Ischemia-Reperfusion and Extensive Hepatectomy. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-12.	0.5	1
8	miR-124-3p Suppresses the Invasiveness and Metastasis of Hepatocarcinoma Cells via Targeting CRKL. Frontiers in Molecular Biosciences, 2020, 7, 223.	1.6	17
9	miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway. Biomedicine and Pharmacotherapy, 2020, 127, 110215.	2.5	17
10	A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 70.	3.5	11
11	Bidirectional interaction of lncRNA AFAP1-AS1 and CRKL accelerates the proliferative and metastatic abilities of hepatocarcinoma cells. Journal of Advanced Research, 2020, 24, 121-130.	4.4	12
12	GRIMâ€'19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade. Oncology Letters, 2020, 19, 4115-4121.	0.8	2
13	CRKII overexpression promotes the in�vitro proliferation, migration and invasion potential of murine hepatocarcinoma Hcaâ€'P cells. Oncology Letters, 2019, 17, 5169-5174.	0.8	2
14	miR-4521-FAM129A axial regulation on ccRCC progression through TIMP-1/MMP2/MMP9 and MDM2/p53/Bcl2/Bax pathways. Cell Death Discovery, 2019, 5, 89.	2.0	34
15	miR-429 suppresses tumor migration and invasion by targeting CRKL in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and epithelial-mesenchymal transition. Scientific Reports, 2018, 8, 2375.	1.6	47
16	Annexin A5 regulates hepatocarcinoma malignancy via CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways. Cell Death and Disease, 2018, 9, 637.	2.7	30
17	Anxa5 mediates the in vitro malignant behaviours of murine hepatocarcinoma Hca-F cells with high lymph node metastasis potential preferentially via ERK2/p-ERK2/c-Jun/p-c-Jun(Ser73) and E-cadherin. Biomedicine and Pharmacotherapy, 2016, 84, 645-654.	2.5	12
18	Akbu-LAAO exhibits potent anti-tumor activity to HepG2 cells partially through produced H2O2 via TGF- \hat{l}^2 signal pathway. Scientific Reports, 2016, 5, 18215.	1.6	25

#	Article	IF	CITATIONS
19	ANXA5 level is linked to <i>in vitro</i> and <i>in vivo</i> tumor malignancy and lymphatic metastasis of murine hepatocarcinoma cell. Future Oncology, 2016, 12, 31-42.	1.1	12
20	ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun. Oncotarget, 2016, 7, 16297-16310.	0.8	12
21	Role of annexin A6 in cancer. Oncology Letters, 2015, 10, 1947-1952.	0.8	66
22	Annexin A11 knockdown inhibits in vitro proliferation and enhances survival of Hca-F cell via Akt2/FoxO1 pathway and MMP-9 expression. Biomedicine and Pharmacotherapy, 2015, 70, 58-63.	2.5	15
23	Annexin A4 and cancer. Clinica Chimica Acta, 2015, 447, 72-78.	0.5	43
24	CRKL knockdown promotes in vitro proliferation, migration and invasion, in vivo tumor malignancy and lymph node metastasis of murine hepatocarcinoma Hca-P cells. Biomedicine and Pharmacotherapy, 2015, 71, 84-90.	2.5	12
25	rAdinbitor, a disintegrin from Agkistrodon halys brevicaudus stejneger, inhibits tumorigenicity of hepatocarcinoma via enhanced anti-angiogenesis and immunocompetence. Biochimie, 2015, 116, 34-42.	1.3	4
26	CRKL overexpression suppresses in vitro proliferation, invasion and migration of murine hepatocarcinoma Hca-P cells. Biomedicine and Pharmacotherapy, 2015, 69, 11-17.	2.5	18
27	The role of CT10 regulation of kinase-like in cancer. Future Oncology, 2014, 10, 2687-2697.	1.1	13
28	Annexin A11 in disease. Clinica Chimica Acta, 2014, 431, 164-168.	0.5	51
29	Galectin-3 in cancer. Clinica Chimica Acta, 2014, 431, 185-191.	0.5	135
30	Annexin A5 as a potential marker in tumors. Clinica Chimica Acta, 2014, 427, 42-48.	0.5	81
31	Comparative binding affinities of flavonoid phytochemicals with bovine serum albumin. Iranian Journal of Pharmaceutical Research, 2014, 13, 1019-28.	0.3	25
32	Potential role of annexin A7 in cancers. Clinica Chimica Acta, 2013, 423, 83-89.	0.5	45
33	The role of annexin A3 playing in cancers. Clinical and Translational Oncology, 2013, 15, 106-110.	1.2	69
34	Novel insight into the role of GAPDH playing in tumor. Clinical and Translational Oncology, 2013, 15, 167-172.	1.2	105
35	Potential role of Anxa1 in cancer. Future Oncology, 2013, 9, 1773-1793.	1.1	101
36	Caveolin-1 interferes cell growth of lung cancer NCI-H446 cell through the interactions with phospho-ERK1/2, estrogen receptor and progestin receptor. Biomedicine and Pharmacotherapy, 2012, 66, 242-248.	2.5	11

#	Article	IF	CITATIONS
37	The association of annexin A2 and cancers. Clinical and Translational Oncology, 2012, 14, 634-640.	1.2	67
38	Proteomic research progress in lymphatic metastases of cancers. Clinical and Translational Oncology, 2012, 14, 21-30.	1.2	22
39	Purification and Characterization of an Endo-d-arabinase Produced by Cellulomonas. Protein Journal, 2012, 31, 51-58.	0.7	2
40	Changes in Protein Profile in Cecum of Mouse with Intestinal Dysbacteriosis Induced by Ceftriaxone Sodium. Journal of Hard Tissue Biology, 2011, 20, 93-98.	0.2	2
41	Biochemical, functional and structural characterization of Akbu-LAAO: A novel snake venom l-amino acid oxidase from Agkistrodon blomhoffii ussurensis. Biochimie, 2010, 92, 343-349.	1.3	46
42	Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates provide potential protein markers for tumor malignancy attributes to lymphatic metastasis. Proteomics, 2009, 9, 3285-3302.	1.3	49
43	A novel phospholipase A2 from Agkistrodon blomhoffii ussurensis venom: Purification, proteomic, functional and structural characterizations. Biochimie, 2009, 91, 558-567.	1.3	18
44	Highâ€performance liquid chromatography/nanoâ€electrospray ionization tandem mass spectrometry, twoâ€dimensional difference inâ€gel electrophoresis and gene microarray identification of lymphatic metastasisâ€associated biomarkers. Rapid Communications in Mass Spectrometry, 2008, 22, 3172-3178.	0.7	48
45	Characterization of a fibrinolytic enzyme (ussurenase) from Agkistrodon blomhoffii ussurensis snake venom: Insights into the effects of Ca2+ on function and structure. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 1340-1348.	1.1	27